Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Aplastic Anemia
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
Rationale: Chemotherapy with fludarabine, cyclophosphamide and anti-thymocyte globulin may
induce the engraftment cross the immunologic barrier in the setting of HLA-haploidentical
allogeneic hematopoietic cell transplantation. In addition, depletion CD3±CD19 cells may
contribute to prevent developing severe acute graft versus host disease (GVHD) in
haploidentical transplantation.
Purpose: This phase I/II trial is to evaluate the safety and efficacy of fludarabine,
cyclophosphamide and antithymocyte globulin with CD3±CD19 depleted graft from haploidentical
donors in treating patients with aplastic anemia.